SCHEMBL22299552

SCHEMBL22299552

COc1ccc(C(C)CCC=C(C)C)c(O)c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.68
PTPN1 P18031 1/20 0.49
TYR P14679 2/20 0.44
BCHE P06276 2/20 0.44
ACHE P22303 1/20 0.44
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
TRIM24 O15164 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP19A1 P11511 3/20 0.39
ALOX5 P09917 1/20 0.39
PTGS2 P35354 1/20 0.39
GSK3B P49841 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22299561 0.86 SRC (0.52) SRCPTPN1TYRBCHEACHE
SCHEMBL29571282 0.81 SRC (1.00) SRCPTPN1ALDH1A1GSK3B
SCHEMBL16749882 0.81 SRC (1.00) SRCPTPN1ALDH1A1GSK3B
SCHEMBL16749879 0.81 SRC (1.00) SRCPTPN1ALDH1A1GSK3B
SCHEMBL31545696 0.81 SRC (1.00) SRCPTPN1ALDH1A1GSK3B
SCHEMBL29412614 0.81 SRC (1.00) SRCPTPN1ALDH1A1GSK3B
SCHEMBL22299950 0.80 SRC (0.56) SRCPTPN1BCHEACHEGSK3B
SCHEMBL24278908 0.79 SRC (0.71) SRCPTPN1PPARGPPARAALDH1A1
SCHEMBL31545802 0.78 SRC (0.69) SRCPTPN1PPARGALDH1A1CYP3A4
SCHEMBL11961096 0.77 TYR (0.59) TYRBCHEACHETRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220105051-A1 COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY Cava Healthcare Inc. (CA) 2022-04-07 US disclosed
WO-2020154811-A9 COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY Cava Healthcare Inc. (CA) 2020-09-17 WO disclosed
WO-2020154811-A1 COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY Cava Healthcare Inc. (CA) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220105051-A1 COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY HDAC1, TAP1, HDAC11 SRC 2561/4885PTPN1 2769/4885TYR 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.